公开(公告)号：EP1383399A1

公开(公告)日：2004-01-28

申请号：EP02728516.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA,as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： BARTELS, Stephen, Paul ,  BAUSTIAN, Cara, Larraine ,  SOUERWINE, David, A. ,  BUNCE, George, Edwin ,  ELLENBOGEN, Leon ,  FERRIS, Federick, L., III ,  KINOSHITA, Jin ,  SMITH, James, Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

摘要： A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

公开(公告)号：EP1383399B1

公开(公告)日：2004-11-03

申请号：EP02728516.2

申请日：2002-03-19

申请人： BAUSCH & LOMB INCORPORATED ,  GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS ,  Wyeth

发明人： BARTELS, Stephen, Paul ,  BAUSTIAN, Cara, Larraine ,  SOUERWINE, David, A. ,  BUNCE, George, Edwin ,  ELLENBOGEN, Leon ,  FERRIS, Federick, L., III ,  KINOSHITA, Jin ,  SMITH, James, Cecil, Jr.

IPC分类号： A23L1/303 ,  A23L1/304 ,  A61K31/375 ,  A61K31/355 ,  A61K31/07 ,  A61K33/30 ,  A61K33/34

CPC分类号： A61K33/34 ,  A23L5/44 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/07 ,  A61K31/355 ,  A61K31/375 ,  A61K33/30 ,  A61K2300/00 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/211 ,  A23V2250/1642 ,  A23V2250/1588 ,  A23V2250/2104 ,  A23V2250/2132 ,  A23V2250/702

摘要： A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

摘要翻译： 一种营养或膳食补充剂组合物，其通过降低患早期年龄相关性黄斑病的患晚期或高龄相关性黄斑变性的风险，通过预防，稳定，逆转和/或治疗视力丧失来增强和促进视网膜健康 退化。 营养或膳食补充剂组合物同样可以降低与白内障发展相关的视力丧失的风险。 营养或膳食补充剂组合物的基本成分是维生素C，维生素E，β-胡萝卜素，锌和铜。 基本成分优选以适于口服摄入的片剂形式提供。 优选地，组合物以每日两次服用一次或两次片剂的形式服用。

公开(公告)号：EP1542687A1

公开(公告)日：2005-06-22

申请号：EP03770361.8

申请日：2003-09-19

申请人： BAUSCH & LOMB INCORPORATED

发明人： PFEFFER, Bruce, Alan ,  FLICK, Rosemarie, Beth ,  SHAMS, Naveed, Bin, Kamal ,  BARTELS, Stephen, Paul

IPC分类号： A61K31/4453 ,  C07D211/16 ,  C07D223/22 ,  C07D279/22

CPC分类号： C07D295/205 ,  C07C275/10 ,  C07C281/18 ,  C07D223/26 ,  C07D279/22

摘要： Small organic molecules capable of effecting a 'pharmacological trabeculocanalotomy' in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

公开(公告)号：EP1542687B1

公开(公告)日：2009-01-28

申请号：EP03770361.8

申请日：2003-09-19

申请人： BAUSCH & LOMB INCORPORATED

发明人： PFEFFER, Bruce, Alan ,  FLICK, Rosemarie, Beth ,  SHAMS, Naveed, Bin, Kamal ,  BARTELS, Stephen, Paul

IPC分类号： A61K31/4453 ,  C07D211/16 ,  C07D223/22 ,  C07D279/22

CPC分类号： C07D295/205 ,  C07C275/10 ,  C07C281/18 ,  C07D223/26 ,  C07D279/22

摘要： Small organic molecules capable of effecting a 'pharmacological trabeculocanalotomy' in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

公开(公告)号：EP1641435A2

公开(公告)日：2006-04-05

申请号：EP04755319.3

申请日：2004-06-15

申请人： BAUSCH & LOMB INCORPORATED

发明人： SHAFIEE, Afshin ,  SALAMONE, Joseph, C. ,  DHARMENDRA, Jani ,  BARTELS, Stephen, Paul ,  KUNZLER, Jay, F.

IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K31/573 ,  A61P27/02

CPC分类号： A61K9/0051 ,  A61K9/1647

摘要： A Chemical erosion controlled drug delivery system to be inserted into the posterior segment of the eye, comprising a mixture of a biodegradable polymer (preferably a poly(lactide-co-glycolide), PLGA) and a hydrophobic pharmaceutically-active agent.